News related to Regenerative Medicine, Tissue Engineering, Medical devices, Pharmaceutical industry with focus on achievements and the legal, ethical, and regulatory aspects of the field

FDA’s Draft Guidances for the calendar year 2017

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has published a Guidance Agenda with planned new and revised Draft Guidances for the calendar year 2017.

Changes are expected within documents of several categories: Advertising, Biopharmaceutics, Biosimilarity, Clinical/Antimicrobial, Clinical/Medical, Clinical Pharmacology, Clinical/Statistical, Drug Safety, Electronic Submissions, Generics, Labeling, Pharmaceutical Quality/CMC, Pharmaceutical Quality/Manufacturing Standards (CGMP), Pharmacology/Toxicology, Procedural, User Fees


Write a Comment

Your email address will not be published. Required fields are marked *

Drug Device Combination – mała rewolucja ?

Przysłuchując się dzisiejszemu spotkaniu Multi-stakeholder webinar to support implementation of the Medical Devices Regulation …

Medical device file / Dokumentacja wyrobu medycznego – ISO 13485

Medical device file / Dokumentacja wyrobu medycznego wymieniona w punkcie 4.2.3 Normy PN-EN ISO 13485 czasem nazywana przez …

UDI a wyroby Drug Device Combination Products

System niepowtarzalnych kodów identyfikacyjnych wyrobów ( „systemem UDI”), opisany w załączniku VI część C …